{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:15:05Z","timestamp":1787501705921,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent. We report the first assessment of its efficacy and safety in correcting renal anemia in a population of 139 nondialysis chronic kidney disease patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>Chronic kidney disease patients who were not on dialysis and not receiving treatment with erythropoiesis-stimulating agents in the 12 weeks before study drug administration were sequentially assigned to one of 10 cohorts; cohorts differed in starting peginesatide dose (different body weight-based or absolute doses), route of administration (intravenous or subcutaneous), and frequency of administration (every 4 or 2 weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across all cohorts, 96% of patients achieved a hemoglobin response. A dose-response relationship was evident for hemoglobin increase. Comparable subcutaneous and intravenous peginesatide doses produced similar hemoglobin responses. Rapid rates of hemoglobin rise and hemoglobin excursions &gt;13 g\/dl tended to occur more frequently with every-2-weeks dosing than they did with every-4-weeks dosing. The range of final median doses in the every-4-weeks dosing groups was 0.019 to 0.043 mg\/kg. Across all cohorts, 20% of patients reported serious adverse events (one patient had a possibly drug-related serious event) and 81% reported adverse events (11.5% reported possibly drug-related events); these events were consistent with those routinely observed in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that peginesatide administered every 4 weeks can increase and maintain hemoglobin in nondialysis chronic kidney disease patients. Additional long-term data in larger groups of patients are required to further elucidate the efficacy and safety of this peptide-based erythropoiesis-stimulating agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.10831210","type":"journal-article","created":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T21:34:23Z","timestamp":1316727263000},"page":"2579-2586","source":"Crossref","is-referenced-by-count":25,"title":["Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients"],"prefix":"10.2215","volume":"6","author":[{"given":"Iain C.","family":"Macdougall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi","family":"Yaqoob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Mikhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"MacPhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mysliwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olgierd","family":"Smolenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142aw","family":"Su\u0142owicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna R.","family":"Polu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Duliege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20230811","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.1990.03440060071035","article-title":"The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group","volume":"263","author":"Evans","year":"1990","journal-title":"JAMA"},{"key":"R2-7-20230811","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.ajkd.2004.08.024","article-title":"Anemia and health-related quality of life in adolescents with chronic kidney disease","volume":"44","author":"Gerson","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R3-7-20230811","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0149-2918(03)80170-4","article-title":"The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review","volume":"25","author":"Ross","year":"2003","journal-title":"Clin Ther"},{"key":"R4-7-20230811","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","article-title":"Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial","volume":"111","author":"Eschbach","year":"1989","journal-title":"Ann Intern Med"},{"key":"R8-7-20230811","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.exphem.2006.05.012","article-title":"Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia","volume":"34","author":"Fan","year":"2006","journal-title":"Exp Hematol"},{"key":"R9-7-20230811","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2006-04-015818","article-title":"Evaluation of the safety and pharmacodynamics of HematideTM, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers","volume":"108","author":"Stead","year":"2006","journal-title":"Blood"},{"key":"R10-7-20230811","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMoa074037","article-title":"A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia","volume":"361","author":"Macdougall","year":"2009","journal-title":"N Engl J Med"},{"key":"R11-7-20230811","first-page":"20","article-title":"European best practice guidelines 6\u20138: Assessing and optimizing iron stores","volume":"15","author":"Macdougall","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R12-7-20230811","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R13-7-20230811","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/ajkd.2002.34881","article-title":"Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients","volume":"40","author":"Besarab","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R14-7-20230811","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ndt\/17.suppl_5.66","article-title":"Optimizing the use of erythropoietic agents: Pharmacokinetic and pharmacodynamic considerations","volume":"17","author":"Macdougall","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R15-7-20230811","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","article-title":"Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients","volume":"62","author":"Vanrenterghem","year":"2002","journal-title":"Kidney Int"},{"key":"R16-7-20230811","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ndt\/18.2.362","article-title":"Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R17-7-20230811","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/ndt\/gfh106","article-title":"Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients","volume":"19","author":"Brunkhorst","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R18-7-20230811","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00730306","article-title":"Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease","volume":"1","author":"Macdougall","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-7-20230811","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000111115","article-title":"C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks","volume":"28","author":"Spinowitz","year":"2008","journal-title":"Am J Nephrol"},{"key":"R20-7-20230811","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.exphem.2007.05.007","article-title":"Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model","volume":"35","author":"Woodburn","year":"2007","journal-title":"Exp Hematol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201111000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:21Z","timestamp":1786369281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201111000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.10831210","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}